Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Adverse events reported following live, cold-adapted, intranasal influenza vaccine.

Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, Chang S, Braun MM, Ball R.

JAMA. 2005 Dec 7;294(21):2720-5. Erratum in: JAMA. 2005 Dec 28;294(24):3092.

PMID:
16333007
2.

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.

Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.

PMID:
25258101
3.

Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.

Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.

Vaccine. 2015 Apr 15;33(16):1987-92. doi: 10.1016/j.vaccine.2015.01.080. Epub 2015 Feb 9.

PMID:
25678241
4.

Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.

Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, Broder K.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):205-13. doi: 10.1093/jpids/piu034. Epub 2014 May 7.

PMID:
26407428
5.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

6.

Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.

Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K.

Vaccine. 2013 Oct 9;31(43):4984-7. doi: 10.1016/j.vaccine.2013.08.001. Epub 2013 Aug 29.

PMID:
23994022
7.

Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6.

8.
9.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

10.

Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.

Kawai AT, Li L, Kulldorff M, Vellozzi C, Weintraub E, Baxter R, Belongia EA, Daley MF, Jacobsen SJ, Naleway A, Nordin JD, Lee GM.

Pharmacoepidemiol Drug Saf. 2014 May;23(5):548-53. doi: 10.1002/pds.3575. Epub 2014 Feb 4.

PMID:
24497128
11.

Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.

Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M.

Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Review.

12.
13.

Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.

Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, Haber P, Martin D, Broder K.

Clin Infect Dis. 2012 Jun;54(11):1608-14. doi: 10.1093/cid/cis256. Epub 2012 Mar 22.

PMID:
22441652
14.

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.

Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS.

Vaccine. 2012 Apr 19;30(19):2989-98. doi: 10.1016/j.vaccine.2012.02.039. Epub 2012 Feb 29.

15.

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.

Toback SL, Ambrose CS, Eaton A, Hansen J, Aukes L, Lewis N, Wu X, Baxter R.

Vaccine. 2013 Apr 3;31(14):1812-8. doi: 10.1016/j.vaccine.2013.01.055. Epub 2013 Feb 6.

16.

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.

Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, Jones JF, LaRussa PS, Garner J, Berger M, Proveaux T, Vellozzi C; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment Network, Broder K, Setse R, Pahud B, Hrncir D, Choi H, Sparks R, Williams SE, Engler RJ, Gidudu J, Baxter R, Klein N, Edwards K, Cano M, Kelso JM.

Vaccine. 2013 Dec 9;31(51):6107-12. doi: 10.1016/j.vaccine.2013.09.066. Epub 2013 Oct 8.

PMID:
24120547
17.

Guillain-Barré syndrome following influenza vaccination.

Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT.

JAMA. 2004 Nov 24;292(20):2478-81.

PMID:
15562126
18.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
19.

Adverse events associated with intranasal influenza vaccine in the United States.

Vasu N, Ghaffari G, Craig ET, Craig TJ.

Ther Adv Respir Dis. 2008 Aug;2(4):193-8. doi: 10.1177/1753465808093933. Review. Erratum in: Ther Adv Respir Dis. 2008 Dec;2(6):423.

PMID:
19124371
20.

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.

Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J.

JAMA. 1999 Jul 14;282(2):137-44.

PMID:
10411194

Supplemental Content

Support Center